<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T00:49:09Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/49087" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/49087</identifier><datestamp>2025-12-05T10:08:16Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478929</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>On the existence and function of galanin receptor heteromers in the central nervous system</dc:title>
   <dc:creator>Fuxe, Kjell</dc:creator>
   <dc:creator>Borroto Escuela, Dasiel Oscar</dc:creator>
   <dc:creator>Romero Fernández, Wilber</dc:creator>
   <dc:creator>Tarakanov, Alexander O.</dc:creator>
   <dc:creator>Calvo, Feliciano</dc:creator>
   <dc:creator>Garriga, Pere</dc:creator>
   <dc:creator>Tena, Mercé</dc:creator>
   <dc:creator>Narváez, Manuel</dc:creator>
   <dc:creator>Millón, Carmelo</dc:creator>
   <dc:creator>Parrado, Concepción</dc:creator>
   <dc:creator>Ciruela Alférez, Francisco</dc:creator>
   <dc:creator>Agnati, Luigi F.</dc:creator>
   <dc:creator>Narváez, José A.</dc:creator>
   <dc:creator>Díaz Cabiale, Zaida</dc:creator>
   <dc:subject>Receptors de serotonina</dc:subject>
   <dc:subject>Sistema nerviós central</dc:subject>
   <dc:subject>Proteïnes G</dc:subject>
   <dc:subject>Serotonin receptors</dc:subject>
   <dc:subject>Central nervous system</dc:subject>
   <dc:subject>G Proteins</dc:subject>
   <dc:description>Galanin receptor (GalR) subtypes 1-3 linked to central galanin neurons may form heteromers with each other and other types of G protein-coupled receptors in the central nervous system (CNS). These heteromers may be one molecular mechanism for galanin peptides and their N-terminal fragments (gal 1-15) to modulate the function of different types of glia-neuronal networks in the CNS, especially the emotional and the cardiovascular networks. GalR-5-HT1A heteromers likely exist with antagonistic GalR-5-HT1A receptor-receptor interactions in the ascending midbrain raphe 5-HT neuron systems and their target regions. They represent a novel target for antidepressant drugs. Evidence is given for the existence of GalR1-5-HT1A heteromers in cellular models with trans-inhibition of the protomer signaling. A GalR1-GalR2 heteromer is proposed to be a galanin N-terminal fragment preferring receptor (1-15) in the CNS. Furthermore, a GalR1-GalR2-5-HT1A heterotrimer is postulated to explain why only galanin (1-15) but not galanin (1-29) can antagonistically modulate the 5-HT1A receptors in the dorsal hippocampus rich in gal fragment binding sites. The results underline a putative role of different types of GalR-5-HT1A heteroreceptor complexes in depression. GalR antagonists may also have therapeutic actions in depression by blocking the antagonistic GalR-NPYY1 receptor interactions in putative GalR-NPYY1 receptor heteromers in the CNS resulting in increases in NPYY1 transmission and antidepressant effects. In contrast the galanin fragment receptor (a postulated GalR1-GalR2 heteromer) appears to be linked to the NPYY2 receptor enhancing the affinity of the NPYY2 binding sites in a putative GalR1-GalR2-NPYY2 heterotrimer. Finally, putative GalR-α2-adrenoreceptor heteromers with antagonistic receptor-receptor interactions may be a widespread mechanism in the CNS for integration of galanin and noradrenaline signals also of likely relevance for depression</dc:description>
   <dc:date>2014-01-22T10:05:24Z</dc:date>
   <dc:date>2014-01-22T10:05:24Z</dc:date>
   <dc:date>2012-10-26</dc:date>
   <dc:date>2014-01-22T10:05:24Z</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>1664-2392</dc:identifier>
   <dc:identifier>https://hdl.handle.net/2445/49087</dc:identifier>
   <dc:identifier>617235</dc:identifier>
   <dc:identifier>23112793</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Reproducció del document publicat a: http://dx.doi.org/10.3389/fendo.2012.00127</dc:relation>
   <dc:relation>Frontiers in Endocrinology, 2012, vol. 3, p. 1-12</dc:relation>
   <dc:relation>http://dx.doi.org/10.3389/fendo.2012.00127</dc:relation>
   <dc:rights>cc-by (c) Fuxe, Kjell et al., 2012</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>12 p.</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Frontiers Media</dc:publisher>
   <dc:source>Articles publicats en revistes (Patologia i Terapèutica Experimental)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>